NIH mark National Institutes of Health 2003 Clinical Center Profile

Skip left navigation list link group.Contents

Introduction

Message from the Director

Historical Highlights

Clinical Center Governance and Accreditation

Organizational Structure and Programs

The Mark O. Hatfield Clinical Research Center

Preparing for the Clinical Research Center Activation

The Edmond J. Safra Family Lodge

Clinical Research Initiatives

Clinician Highlight

Clinical Research Training Programs

Organizational Effectiveness and Efficiency Initiatives

Public Outreach

End of left navigation list link group.

Organizational Structure and Programs

Breakdown of Clinical Trials
(Onsite Intramural Protocols) Fiscal Year 2002

Clinical Trials Proceed Through Four Phases

Phase I: Researchers test a new drug or treatment in a small group of people (20–80) for the first time to evaluate its safety, determine a safe dosage range and identify side effects.

Phase II: The study drug or treatment is given to a larger group of people (100–300) to see if it is effective and to further evaluate its safety.

Phase III: The study drug or treatment is given to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will ensure safe usage.

Phase IV: These studies are done after the drug or treatment has been marketed. The testing continues to collect information about the effect of the drug or treatment in various populations and determine any side effects from long-term use.

Chart: Total Clinical Trials 516; Phase I: 180, Phase II: 285, Phase III: 35, Phase IV: 16


See more information:
Protocols by Research Type >
Patient Activity >
Home States of all Active Clinical Center Patients >

< Return to the Organization Structure and Programs main page